These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 21420567)

  • 21. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis.
    Tasneen R; Li SY; Peloquin CA; Taylor D; Williams KN; Andries K; Mdluli KE; Nuermberger EL
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5485-92. PubMed ID: 21930883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice.
    Veziris N; Lounis N; Chauffour A; Truffot-Pernot C; Jarlier V
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4015-9. PubMed ID: 16189074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New drugs for tuberculosis.
    Grassi C; Peona V
    Eur Respir J Suppl; 1995 Sep; 20():714s-718s. PubMed ID: 8590571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Once-weekly rifapentine-containing regimens for treatment of tuberculosis in mice.
    Grosset J; Lounis N; Truffot-Pernot C; O'Brien RJ; Raviglione MC; Ji B
    Am J Respir Crit Care Med; 1998 May; 157(5 Pt 1):1436-40. PubMed ID: 9603120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Dec; 60(48):1650-3. PubMed ID: 22157884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rifapentine for the treatment of pulmonary tuberculosis.
    Munsiff SS; Kambili C; Ahuja SD
    Clin Infect Dis; 2006 Dec; 43(11):1468-75. PubMed ID: 17083024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tuberculosis: the drug development pipeline at a glance.
    Villemagne B; Crauste C; Flipo M; Baulard AR; Déprez B; Willand N
    Eur J Med Chem; 2012 May; 51():1-16. PubMed ID: 22421275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FDA approves rifapentine for the treatment of pulmonary tuberculosis.... Food and Drug Administration.
    Roehr B
    J Int Assoc Physicians AIDS Care; 1998 Aug; 4(8):19-25. PubMed ID: 11365728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Issues in the treatment of active tuberculosis in human immunodeficiency virus-infected patients.
    Schluger NW
    Clin Infect Dis; 1999 Jan; 28(1):130-5. PubMed ID: 10028083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Turning intermittent regimens into daily regimens using blister-packs. An exploration in murine tuberculosis.
    Guy A; Dickinson JM; Mitchison DA
    Tuber Lung Dis; 1993 Oct; 74(5):310-6. PubMed ID: 8260664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Antitubercular chemotherapy].
    Jouveshomme S; Dautzenberg B
    Rev Mal Respir; 1997 Dec; 14 Suppl 5():S88-104. PubMed ID: 9496594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tuberculosis treatment: dangerous regimens?
    Rieder HL; Arnadottir T; Trébucq A; Enarson DA
    Int J Tuberc Lung Dis; 2001 Jan; 5(1):1-3. PubMed ID: 11263509
    [No Abstract]   [Full Text] [Related]  

  • 33. Short-course tuberculosis chemotherapy studies conducted in Poland during the past decade.
    Snider DE; Zierski M; Graczyk J; Bek E; Farer LS
    Eur J Respir Dis; 1986 Jan; 68(1):12-8. PubMed ID: 3512281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes.
    Lienhardt C; Vernon A; Raviglione MC
    Curr Opin Pulm Med; 2010 May; 16(3):186-93. PubMed ID: 20216421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Completing tuberculosis prophylaxis in jail: targeting treatment and comparison of rifampin/pyrazinamide with isoniazid regimens.
    Lincoln T; Brannan GL; Lynch V; Conklin TJ; Clancey T; Rose DN; Tuthill RJ
    Int J Tuberc Lung Dis; 2004 Mar; 8(3):306-11. PubMed ID: 15139468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Tuberculosis Research Centre.
    Int J Tuberc Lung Dis; 1997 Dec; 1(6):509-17. PubMed ID: 9487448
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New anti-tuberculosis drugs in clinical trials with novel mechanisms of action.
    Rivers EC; Mancera RL
    Drug Discov Today; 2008 Dec; 13(23-24):1090-8. PubMed ID: 18840542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial.
    Dorman SE; Nahid P; Kurbatova EV; Goldberg SV; Bozeman L; Burman WJ; Chang KC; Chen M; Cotton M; Dooley KE; Engle M; Feng PJ; Fletcher CV; Ha P; Heilig CM; Johnson JL; Lessem E; Metchock B; Miro JM; Nhung NV; Pettit AC; Phillips PPJ; Podany AT; Purfield AE; Robergeau K; Samaneka W; Scott NA; Sizemore E; Vernon A; Weiner M; Swindells S; Chaisson RE;
    Contemp Clin Trials; 2020 Mar; 90():105938. PubMed ID: 31981713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Tuberculosis therapy 1990].
    Villiger B
    Schweiz Rundsch Med Prax; 1990 May; 79(21):670-4. PubMed ID: 2190295
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Tuberculosis-current therapeutic principles].
    Greinert U; Zabel P
    Internist (Berl); 2003 Nov; 44(11):1394-405. PubMed ID: 14689075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.